Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06205316 · ClinicalTrials.gov registry record · Phase 3
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
A Phase 3 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 118
- Enrollment target
- 6
- Study locations
NCT06205316 is a Phase 3 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 118 participants, below the 152-participant average among 28 other Stage IV Prostate Cancer AJCC v8 trials with a reported enrollment target (22% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT06205316, a Phase 3 study of Stage IV Prostate Cancer AJCC v8 and Stage III Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 118 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to a limited number of sites (oligometastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumors cells and have fewer side effects. SBRT may work just as well as hypofractionated radiation therapy at treating patients with biochemically recurrent or oligometastatic prostate cancer, but with a shorter treatment time and possibly fewer side effects.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Positron Emission Tomography
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Antiandrogen Therapy
- RADIATION Hypofractionated Radiation Therapy
Study Locations (6)
Minnesota
- Mayo Clinic Health System in Albert Lea - Albert Lea
- Mayo Clinic Health System - Mankato - Mankato
- Mayo Clinic in Rochester - Rochester
Wisconsin
- Mayo Clinic Health System-Eau Claire Clinic - Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare - La Crosse
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2030-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06205316
The ClinicalTrials.gov registry entry for NCT06205316 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 28 other Stage IV Prostate Cancer AJCC v8 trials with a reported enrollment target (22% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Stage IV Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06205316 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, Wisconsin, Arizona.
Frequently Asked Questions
What is clinical trial NCT06205316 about?
NCT06205316 is a clinical study titled "SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma". This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary ...
What is the current status of trial NCT06205316?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 118 participants. The study started on 2024-01-22. Estimated completion is 2030-01-22.
What conditions does trial NCT06205316 study?
This clinical trial studies the following conditions: Stage IV Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Biochemically Recurrent Prostate Carcinoma.
What interventions are being tested in trial NCT06205316?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Positron Emission Tomography (PROCEDURE), Stereotactic Body Radiation Therapy (RADIATION), Antiandrogen Therapy (DRUG), Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06205316?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06205316 being conducted?
This trial has 6 study locations across Arizona, Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RECRUITING · Phase 3
-
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
RECRUITING · Phase 2
-
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
RECRUITING · Phase 2
-
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Stage IV Prostate Cancer AJCC v8
All registered trials for this condition
Stage III Prostate Cancer AJCC v8
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.